Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

Researchers conducted an observational study to compare the risk for dementia associated with both the live and recombinant shingles vaccines. The recombinant herpes zoster (shingles) vaccine is ...

GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new ...

Derived from the Latin adjuvare (to help or aid), adjuvants enhance antigen-specific vaccine immunogenicity. Added only when ...

reactogenicity and safety of Arexvy (Respiratory Syncytial Virus Vaccine) when co-administered with Shingrix (Zoster Vaccine). Shingrix is approved to prevent shingles (herpes zoster) in adults ...

Trial met primary endpoint, non-inferior immune response for both vaccines when co-administered compared with separate administration Co-administration of the RSV and shingles adjuvanted vaccines ...

A vaccine for the prevention of shingles in adults aged 50 and over and those aged 18 and over at increased risk KUALA LUMPUR, Malaysia, Sept. 13, 2024 /PRNewswire/ -- GlaxoSmithKline ...

GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.

Findings showed a noninferior immune response for both vaccines when coadministered compared with separate administration. Topline results were announced from a phase 3 study assessing the immune ...

2 Len Friedland, MD, Vice President of Scientific Affairs and Public Health, GSK, said: “We are excited to share data on the co‑administration of our RSV and shingles vaccines. Adult ...

Trial met primary endpoint, non-inferior immune response for both vaccines when co-administered compared with separate administration Co-administration of the RSV and shingles adjuvanted vaccines was ...